HHorinouchi· @HHorinouchi · X·· 2 天前评分60
正文 · 原文
🆙#ESMO26 Proffered Paper II: #LCSM Mets 🔥Dalmelitinib Plus Aumolertinib Versus Platinum-Based Chemotherapy in Advanced NSCLC Patients With MET Amplification Post EGFR TKI: A Randomized, Phase 3 Study 🎙️Dr. Ziming Li 🔢2615O 🎯Met Primary Endpoint: IRC-PFS 6.2 vs 4.4mo (HR 0.601, p<0.001; n=314); ORR 59.6% vs 38.6%; OS HR 0.840 (Immature, 46.8% Crossover); Grade≥3 TEAEs 50.0% vs 51.0% ☑️NCT06110663 🔗 https://t.co/M4ccE0ikXo @OncoAlert @Larvol @myESMO @IASLC @EGFRResisters
热度 1 · 1 赞 · 0 回复 · 0 转发
会议摘要
NCT06110663NCT06110663按 - **标题 / Title：** A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy 对上
- **标题 / Title：** A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy读摘要原文 →来源：HHorinouchi · x.com